The Centers for Medicare & Medicaid Services Friday delayed, from May 15 to Dec. 15, the effective date for its final rule codifying how it defines “reasonable and necessary” coverage for items and services furnished under Medicare Parts A and B. The rule also establishes a Medicare coverage pathway for innovative medical devices designated as breakthrough by the Food and Drug Administration. 

CMS said the delay would allow it to address issues raised by stakeholders and determine appropriate next steps. It previously delayed the rule from March 15 to May 15 as part of the Biden administration’s review of new and pending rules and requested public comment on the rule’s underlying facts, law and policy. 

In comments submitted in November, AHA warned against replacing the appropriateness criteria entirely with a consideration of commercial market coverage, noting that such an approach could reduce coverage in the Medicare program and transparency in coverage determinations. Under the final rule, CMS opted not to replace the appropriateness criteria entirely and will issue draft sub-regulatory guidance on the methodology for determining when and how commercial coverage will be determined relevant.
 

Related News Articles

Headline
The AHA Jan. 31 commended Sens. Bill Cassidy, R-La., Catherine Cortez Masto, D-Nev., John Cornyn, R-Texas., and Michael Bennet, D-Colo., on draft legislation…
Headline
The White House Office of Management and Budget Jan. 29 rescinded a memo it issued two days earlier directing federal agencies to temporarily pause federal…
Headline
An analysis by KFF released Jan. 28 found that Medicare Advantage insurers made nearly 50 million prior authorization determinations in 2023. The finding…
Headline
The White House Office of Management and Budget late Jan. 27 issued a memo directing federal agencies to temporarily pause federal grants, loans and other…
Headline
The AHA Jan. 27 voiced support for the Centers for Medicare & Medicaid Services proposed rule on policy and technical changes to Medicare Advantage and…
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…